Search
China Biologic Products: Self-Developed Product Cosmeciclib Approved for Marketing
2025-12-11 /
Read about 0 minute
Author：小编
The CDK2/4/6 inhibitor Cosmeciclib Capsules, independently developed by Chia Tai Tianqing under China Biologic Products, has been approved for marketing. It is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine therapy, and its indications are being expanded. Currently, the market size for breast cancer treatment drugs continues to grow amidst fierce competition. China Biologic Products has comprehensively covered all molecular subtypes and lines of treatment for breast cancer, particularly possessing differentiated products in the HR+/HER2- field. Additionally, the company has extensively covered mainstream therapeutic drugs for breast cancer.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
